Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152462 | 1.00 | ABCB1 (0.45) | ABCB1STSL3MBTL1GPR119KLK7 | |
| SCHEMBL14592677 | 1.00 | ABCB1 (0.45) | ABCB1STSL3MBTL1GPR119KLK7 | |
| SCHEMBL2432631 | 1.00 | ABCB1 (0.45) | ABCB1STSL3MBTL1GPR119KLK7 | |
| SCHEMBL14592644 | 0.91 | ABCB1 (0.42) | ABCB1STSL3MBTL1GPR119KLK7 | |
| SCHEMBL5457099 | 0.91 | ABCB1 (0.42) | ABCB1STSL3MBTL1GPR119KLK7 | |
| SCHEMBL19237001 | 0.88 | HTR2C (0.43) | ABCB1STSL3MBTL1GPR119KLK7 | |
| SCHEMBL31641983 | 0.87 | ABCB1 (0.41) | ABCB1STSL3MBTL1GPR119KLK7 | |
| SCHEMBL31642777 | 0.87 | ABCB1 (0.41) | ABCB1STSL3MBTL1GPR119KLK7 | |
| SCHEMBL5162583 | 0.87 | ABCB1 (0.41) | ABCB1STSL3MBTL1GPR119KLK7 | |
| SCHEMBL2433340 | 0.87 | ABCB1 (0.41) | ABCB1STSL3MBTL1GPR119KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| CN-1391473-A | VLA-4 inhibitor compounds | DAIICHI SEIYAKU CO (JP) | 2003-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | ABCB1 3109/4885STS 1179/4885L3MBTL1 4767/4885 |
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | ABCB1 1901/4885STS 3431/4885L3MBTL1 703/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | ABCB1 2174/4885STS 3507/4885L3MBTL1 428/4885 |
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | ABCB1 835/4885STS 1994/4885L3MBTL1 1686/4885 |
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | ABCB1 2207/4885STS 2480/4885L3MBTL1 668/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | ABCB1 2028/4885STS 3436/4885L3MBTL1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.